+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 32 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, immune response, and early clinical effects of BNT3212, both alone and combined with pumitamig, in adults with advanced solid tumors who have exhausted other treatment options. This first-in-human, open-label study includes dose escalation and expansion phases to find the best dose and assess how the treatments work across different tumor types. The study is divided into four parts Part A and Part B focus on BNT3212 as a single therapy, with dose escalation followed by dose expansion in specific tumor types. Parts C and D evaluate the combination of BNT3212 with a fixed dose of pumitamig, again starting with dose escalation and then expansion cohorts. Treatments are given by intravenous infusion, and doses are adjusted to find the maximum tolerated dose and recommended dose for further study. Participants will undergo regular monitoring including safety assessments, blood tests to study drug levels and immune reactions, and imaging to measure tumor response. Researchers will track side effects, treatment interruptions, and response rates over approximately 31 months. The study also measures progression-free and overall survival. Continuous evaluation of safety and clinical data supports participant well-being throughout the trial.

Age: 18Years +All GendersPhase 1Phase 2
17 locations
E

Actively Recruiting

Researchers are studying RC288, a drug being evaluated for its safety, tolerability, and effectiveness in treating locally advanced unresectable or metastatic malignant solid tumors. The study aims to find the highest safe dose and the recommended dose for further testing while assessing how well the drug works at that dose. This is a Phase III clinical trial sponsored by RemeGen Co., Ltd., involving multiple centers. Participants receive RC288 through intravenous infusion. The study includes six predefined dose levels that increase stepwise in Phase I to determine the maximum tolerated or administered dose. In Phase II, the recommended dose is further tested across various cancer types to evaluate safety and effectiveness. Patients continue treatment until they experience unacceptable side effects, disease progression, or meet criteria for withdrawal. During the study, participants undergo regular assessments including imaging to measure tumor responses, evaluations for adverse events, and monitoring of vital organ functions. Researchers will collect data over 24 months on dose-limiting toxicities, side effect severity, and tumor response rates using established criteria. The trial lasts up to approximately four years with ongoing safety monitoring and efficacy assessments throughout.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
14 locations
R

Actively Recruiting

This clinical trial is designed to compare the duration participants remain free of disease progression when treated with two different combinations of therapies for adults with KRASNRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer. The study focuses on how amivantamab combined with chemotherapy compares to cetuximab combined with chemotherapy in treating this specific cancer type. Participants will be divided into two groups. One group receives amivantamab combined with chemotherapy, either mFOLFOX6 containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and oxaliplatin or FOLFIRI containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan hydrochloride. The other group receives cetuximab combined with the same chemotherapy options. Treatments are given in 28-day cycles and continue until the cancer progresses or other reasons require stopping the treatment. Throughout the study, participants will undergo regular evaluations to monitor how long they remain without disease progression, assessed by independent review and investigators. Other assessments include overall survival, response rates, duration of response, quality of life questionnaires, and safety monitoring up to several years. The study spans several years, with primary outcomes measured up to over four years and additional follow-up extending beyond seven years to gather comprehensive data on treatment effects and patient well-being.

Age: 18Years +All GendersPhase 3
239 locations
P

Actively Recruiting

Researchers are evaluating the drug brenipatide compared to a placebo to see if it works and is safe for adults with Alcohol Use Disorder AUD and hazardous alcohol use. This phase 3 study aims to understand how brenipatide affects drinking patterns over time. Participation in this trial will last about 56 weeks, with careful monitoring throughout. Participants will receive brenipatide or placebo through subcutaneous injections. The study includes escalating doses of brenipatide administered under the skin. Participants must self-inject the study drug or receive assistance from a trained support person if needed. The treatment phase is structured in parallel groups, comparing the drug against placebo. During the study, participants will attend regular visits and be asked to maintain study diaries and complete questionnaires. Researchers will assess changes in drinking patterns using the Timeline Followback Method, daily alcohol consumption, alcohol cravings, and health outcomes such as body weight and quality of life. Blood samples will be collected to measure brenipatide levels and monitor for any immune responses. The study includes safety monitoring and lasts for approximately 56 weeks.

Age: 18Years - 75YearsAll GendersPhase 3
115 locations
R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of claseprubart DNTH103 compared to placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP. This Phase 3 study aims to assess whether claseprubart can improve outcomes in participants with typical or variant forms of CIDP, including motor or multifocal types. The study is sponsored by Dianthus Therapeutics and involves several treatment periods to carefully measure the drugs impact. The study consists of multiple parts Part A includes an open-label phase lasting up to 13 weeks where participants receive an intravenous loading dose of claseprubart followed by subcutaneous injections every two weeks. Part B is a randomized, double-blind period lasting up to 52 weeks where participants who responded in Part A receive either claseprubart or placebo as subcutaneous injections every two weeks. Eligible participants may then join an optional open-label extension lasting up to 104 weeks receiving claseprubart injections every two weeks. A safety follow-up period of 40 weeks follows to monitor long-term effects. Participants will undergo various assessments throughout the study, including evaluations of neurological function and disease activity using scales such as the Adjusted Inflammatory Neuropathy Cause and Treatment INCAT score, Inflammatory Rasch-built Overall Disability Scale I-RODS, grip strength measurements, and other strength and disability scales. Researchers will also monitor for adverse events, measure serum drug concentrations, and evaluate immune responses. The total participation time may extend over several years, with regular visits for treatment administration, monitoring, and safety follow-up.

Age: 18Years - 75YearsAll GendersPhase 3
201 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
A

Actively Recruiting

Researchers are studying nerandomilast as a potential treatment for adults with systemic sclerosis SSc, a condition that causes skin thickening and affects internal organs. This phase 3 trial aims to evaluate whether nerandomilast improves symptoms and slows disease progression in people with limited or diffuse cutaneous SSc who have had disease onset within 7 years of their first non-Raynauds symptom. The study is sponsored by Boehringer Ingelheim and compares nerandomilast to a placebo in a double-blind, randomized design. Participants are randomly assigned to one of two groups one group takes nerandomilast tablets and the other takes placebo tablets. Both types of tablets are film-coated and look the same. Participants take these tablets twice daily. The study lasts from 1 to about 4 years, during which participants attend regular visits and receive phone calls from study staff. The trial includes adults with active disease who may be untreated or on stable immunosuppressive treatments. During the study, participants undergo repeated assessments including blood tests and evaluations of skin thickening, lung function, and overall health. Doctors also monitor internal organs and check for any side effects or safety concerns related to the treatment. The main outcome measured is the time until disease progression or death over up to 4 years. Other outcomes include changes in skin score, lung function, and quality of life. Safety and tolerability are closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
248 locations
C

Actively Recruiting

Colorectal cancer CRC is a common and growing health concern in China, with its incidence increasing faster than the global average. Early detection through screening is crucial to reduce the disease burden, especially in average risk populations where most sporadic cases occur. This trial aims to compare different colorectal cancer screening methods to find effective approaches for the average risk population in China. Participants will be randomly assigned to one of three screening groups a colonoscopy group that receives a single colonoscopy in the first year a FIT group that undergoes annual fecal immunochemical tests for four years, with positive results followed by diagnostic colonoscopy and a FIT plus blood test group that combines annual FIT and blood tests detecting cfDNA methylation, also followed by colonoscopy if positive. All groups will have suspicious lesions removed and examined, followed by annual follow-ups and long-term monitoring. During the study, participants will provide fecal, blood, and tissue samples. Researchers will assess colorectal cancer mortality over 10 years as the primary outcome, along with detection rates of advanced lesions, population compliance, cancer stages, incidence rates, quality of life, and cost-effectiveness over 4 to 10 years. This comprehensive approach includes a 4-year screening phase and extended follow-up to monitor outcomes and safety.

Age: 45Years - 74YearsAll GendersPhase Not Applicable
7 locations
O

Actively Recruiting

Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.

All AgesAll Genders
29 locations

1-10 of 32

1